TR64 / Tarapeutics Science - LARVOL DELTA

A phase I study of TR64, a VEGFR/CSF1R/c-KIT small molecule inhibitor, for the treatment of advanced malignant solid tumors. (ASCO 2025) - P1 | "TR64 exhibits a favorable safety profile and promising efficacy, particularly in SCLC. These findings warrant further investigation in the ongoing dose-expansion study (NCT05649345)."

Metastases • P1 data • Anemia • Breast Cancer • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Gastrointestinal Stromal Tumor • HER2 Breast Cancer • HER2 Positive Breast Cancer • Leukopenia • Lung Cancer • Neutropenia • Oncology • Osteosarcoma • Pancreatic Cancer • Rectal Cancer • Renal Disease • Sarcoma • Small Cell Lung Cancer • Small Intestinal Carcinoma • Solid Tumor • Spindle Cell Sarcoma • CSF1R • HER-2 • KIT

TR64 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=19 | Recruiting | Sponsor: Tarapeutics Science Inc. | Trial completion date: Jan 2025 ➔ Dec 2026 | Trial primary completion date: Jul 2024 ➔ Aug 2026

Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

TR64 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=19 | Recruiting | Sponsor: Tarapeutics Science Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

TR64 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=19 | Not yet recruiting | Sponsor: Tarapeutics Science Inc.

New P1 trial • Oncology • Solid Tumor